Patents Assigned to Wake Forest University
  • Patent number: 10766970
    Abstract: Modified alginates are described herein along with hydrogels comprising the same. A modified alginate may be prepared by reacting alginate and an aromatic compound (e.g., an aromatic amine) and/or pH sensitive compound. The modified alginates, hydrogels, and/or methods described herein may be used to coat and/or encapsulate at least a portion of a bioactive substance, optionally for oral delivery in humans and other animals.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: September 8, 2020
    Assignees: Wake Forest University Health Sciences, Wake Forest University
    Inventors: Mark E. Welker, Emmanuel C. Opara, Surya R. Banks, Amber N. Weissenfluh
  • Patent number: 10758634
    Abstract: Disclosed are novel compounds, complexes, compositions and methods using Zirconium-89 combined with azamacrocyclic chelators in connection with PET. The compositions and methods should provide better diagnostic, prognostic and therapeutic oncology treatments relative to the presently available chelator compositions due to a variety of superior properties of the disclosed compositions. The present invention also relates to a superior method of making these compounds, complexes, compositions that allows one to make compounds/complexes (and thus, compositions) that were previously unattainable.
    Type: Grant
    Filed: March 18, 2017
    Date of Patent: September 1, 2020
    Assignee: Wake Forest University
    Inventors: Thaddeus J. Wadas, Darpan N. Pandya, Nikunj B. Bhatt
  • Patent number: 10752667
    Abstract: Provided herein is a construct comprising, in combination: an EphA3, EphA2 and/or EphB2 binding ligand; and at least one effector molecule. In some embodiments, the at least one effector molecule comprises a therapeutic agent, a nanoparticle, a detectable group, a lipid, or a liposome. In some embodiments, the construct is a fusion protein and/or a covalent conjugate. Further provided is a construct comprising, in combination: a ligand that binds to EphA2, EphA3 and/or EphB2; a ligand that binds to IL-13R?2; and at least one effector molecule. Also provided are methods of use thereof for treating cancer.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: August 25, 2020
    Assignee: Wake Forest University Health Sciences
    Inventors: Waldemar Debinski, Carla Lema Tome, Sara Ferluga, Poonam S. Sonawane
  • Patent number: 10751448
    Abstract: Provided are live, artificial, skin substitute products and methods of making and using the same, such as for wound treatment and compound testing, including compound testing for efficacy, toxicity, penetration, irritation and/or metabolism testing of drug candidates or compositions such as cosmetics. Described herein is an artificial mammalian skin substitute product, comprising: (a) optionally, but in some embodiments preferably, a first (“hypodermis-like”) layer comprising live mammalian adipocytes (e.g., induced pre-adipocytes) in a first hydrogel carrier; (b) a second (“dermis-like”) layer contacting or directly contacting the first layer and comprising live mammalian fibroblast cells and' live mammalian follicle dermal papilla cells in combination in a second hydrogel carrier; (c) a third (“epidermis-like”) layer contacting or directly contacting the second layer (i.e.
    Type: Grant
    Filed: January 11, 2016
    Date of Patent: August 25, 2020
    Assignee: WAKE FOREST UNIVERSITY HEALTH SCIENCES
    Inventors: Anthony Atala, Gayoung Jeong, James J. Yoo, Sang jin Lee, Young-Joon Seol
  • Patent number: 10751447
    Abstract: Vascular scaffolds and methods of fabricating the same are disclosed for tissue engineering of vascular constructs. By combining electrospun matrices with cell sheet technologies, vascular constructs with more mature cell layers can be obtained for reconstruction of blood vessels, heart valves and the like. A engineered smooth muscle cell sheet, wrapped around an electrospun vascular scaffold, is able to provide a mature SMC layer that expresses strong cell-to-cell junction markers and contractile proteins. In addition, preconditioning of the cell sheet covered vascular scaffold maintained cell viability and infiltration into the scaffold.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: August 25, 2020
    Assignee: WAKE FOREST UNIVERSITY HEALTH SCIENCES
    Inventors: Hyunhee Ahn, Young Min Ju, Anthony Atala, Sang Jin Lee
  • Publication number: 20200261419
    Abstract: Provided herein are methods of treatment for kidney stones, e.g., for controlling or inhibiting the formation of calcium oxalate kidney stones by inhibiting the production of glyoxylate and/or oxalate, treatment of primary hyperoxaluria, etc. In some embodiments, methods comprise administering to a subject in need thereof, in combination, an inhibitor of hydroxyproline dehydrogenase (HYPDH), an inhibitor of glycolate oxidase (GO), and/or another agent for the treatment of kidney stones. Compositions for such use or the use of active agents in the manufacture of a medicament for the treatment of kidney stones are also provided.
    Type: Application
    Filed: December 7, 2016
    Publication date: August 20, 2020
    Applicant: Wake Forest University Health Sciences
    Inventors: W. Todd Lowther, Ross P. Holmes, Daniel Yohannes
  • Patent number: 10736945
    Abstract: The present invention provides compositions and methods for treating a myopathy. In certain embodiments, the invention provides compositions and methods for treating, improving muscle function, and prolonging survival in a subject with X-linked myotubular myopathy (XLMTM). The present invention provides a method comprising systemic administration of a composition that induces the increased expression of myotubularin in the muscle of a subject. The invention provides sustained regional and global increases in muscle function.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: August 11, 2020
    Assignees: Wake Forest University Health Sciences, Genethon, Children's Medical Center Corporation
    Inventors: Martin K. Childers, Alan H. Beggs, Ana Maria Buj Bello
  • Publication number: 20200216499
    Abstract: Angiotensin (1-7) analogs are provided. The analogs contain one or more substitutions with non-natural amino acid cis-3-(aminomethyl)cyclobutanecarboxylic acid (ACCA). Also provided are methods of making such analogs and methods for using such analogs as therapeutic compositions to treat or prevent various diseases or conditions.
    Type: Application
    Filed: December 12, 2016
    Publication date: July 9, 2020
    Applicants: WAKE FOREST UNIVERSITY HEALTH SCIENCES, UNIVERSITY COLLEGE DUBLIN
    Inventors: Patricia E. Gallagher, E. Ann Tallant, Francesca Paradisi, Mark C. Chappell
  • Patent number: 10676529
    Abstract: Provided herein are monoclonal antibodies that specifically bind IL-13RA2 with cross-reactivity in humans and canines. Also provided are methods of use of the antibodies in the treatment and monitoring of cancers.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: June 9, 2020
    Assignee: Wake Forest University Health Sciences
    Inventors: Waldemar Debinski, Denise Mazess Herpai
  • Patent number: 10665797
    Abstract: In one aspect, field effect transistors are described herein employing channels formed of hybrid halide perovskite materials. For example, a field effect transistor comprises a source terminal, a drain terminal and a gate terminal wherein a dielectric layer is positioned between the gate terminal and the source and drain terminals. A channel layer is in electrical communication with the source terminal and the drain terminal, the channel layer comprising an organic-inorganic perovskite in contact with a polymeric surface of the dielectric layer.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: May 26, 2020
    Assignees: WAKE FOREST UNIVERSITY, UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Yaochuan Mei, Oana Diana Jurchescu, Zeev Valentine Vardeny, Chuang Zhang
  • Patent number: 10632235
    Abstract: The present invention provides devices and methods that treat damaged spinal cord tissue, such as spinal tissue damaged by disease, infection, or trauma, which may lead to the presence of swelling, compression, and compromised blood flow secondary to interstitial edema.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: April 28, 2020
    Assignee: WAKE FOREST UNIVERSITY HEALTH SCIENCES
    Inventors: Louis C Argenta, David L Carroll, Nicole H Levi, Jie Liu, Michael J Morykwas, Stephen Tatter, William D Wagner
  • Patent number: 10634658
    Abstract: In one aspect, methods are described herein for the selective detection and quantitative analysis of biological molecule compositions. A method described herein comprises providing a mixture comprising biological molecules, such as DNA, RNA or proteins, complexed with a translocating agent, such as another DNA or protein, and non-complexed biological molecules. The mixture is contacted with a membrane comprising at least one nanopore and an electric field is applied across the nanopore to selectively translocate the biological molecules complexed with the translocating agent through the at least one nanopore. Concentration of the complexed biological molecules is determined based on the translocation rate of said molecules.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: April 28, 2020
    Assignee: WAKE FOREST UNIVERSITY HEALTH SCIENCES
    Inventor: Adam R. Hall
  • Patent number: 10590391
    Abstract: Provided herein are isolated populations of kidney cells harvested from differentiated cells of the kidney, wherein the cells have been expanded in vitro. The kidney cells preferably produce erythropoietin (EPO). The kidney cells may also be selected based upon EPO production. Methods of producing an isolated population of EPO producing cells are also provided, and methods of treating a kidney disease resulting in decreased EPO production in a patient in need thereof are provided, including administering the population to the patient, whereby the cells express EPO in vivo in an oxygen tension-dependent manner.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: March 17, 2020
    Assignee: WAKE FOREST UNIVERSITY HEALTH SCIENCES
    Inventors: Anthony Atala, James J. Yoo
  • Patent number: 10571371
    Abstract: The disclosure provides improved materials and methods for optically clearing biological tissue that is subsequently used for deep tissue imaging analysis. Also provided is a description of a microscopic image acquisition methodology in which imagery of intact tissues are acquired to rapidly acquire microscopy data on a whole-organ scale to maximize cost effectiveness for biological microscopy and minimize time spent performing such analysis.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: February 25, 2020
    Assignee: WAKE FOREST UNIVERSITY HEALTH SCIENCES
    Inventors: Frank Marini, George Christ
  • Patent number: 10572999
    Abstract: Methods, systems, computer programs, circuits and workstations are configured to generate at least one two-dimensional weighted CBF territory map of color-coded source artery locations using an automated vascular segmentation process to identify source locations using mutual connectivity in both image and label space.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: February 25, 2020
    Assignee: Wake Forest University Health Sciences
    Inventor: Youngkyoo Jung
  • Patent number: 10562844
    Abstract: Provided herein are compounds of Formula (I), Formula (II), and Formula (III), and compositions comprising the same, as well as methods of use thereof for controlling or inhibiting the formation of calcium oxalate kidney stones, inhibiting the production of glyoxylate and/or oxalate, and/or inhibiting hydroxyproline dehydrogenase (HYPDH).
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: February 18, 2020
    Assignees: Wake Forest University Health Sciences, UAB Research Foundation
    Inventors: W. Todd Lowther, Ross P. Holmes, Daniel Yohannes
  • Patent number: 10547006
    Abstract: In one aspect, composite layers are described herein demonstrating phase-separated architectures which, in some embodiments, can mitigate performance disadvantages of prior organic layers of optoelectronic devices. A composite organic layer described herein comprises nanocluster nodes and carbon nanoparticles disposed in a conjugated polymeric host, wherein the carbon nanoparticles are substantially phase separated from the conjugated polymeric host forming lamellar structures of carbon nanofibrils radiating from the nanocluster nodes.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: January 28, 2020
    Assignee: Wake Forest University
    Inventor: David Carroll
  • Patent number: 10537689
    Abstract: Provided herein is a delivery system, including: (a) an optical sensor configured to detect data to create a map of a patient bodily surface; and (b) a dispenser operatively associated with the optical sensor and configured to deliver compositions (optionally including cells) to the patient bodily surface based upon the data or map. Methods of forming a tissue on a patient bodily surface of a patient in need thereof are also provided, as are methods, systems and computer program products useful for processing patient bodily surface data.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: January 21, 2020
    Assignee: Wake Forest University Health Sciences
    Inventors: James J. Yoo, Anthony Atala, Kyle W. Binder, Mohammad Z. Albanna, Weixin Zhao, Dennis Dice, Tao Xu
  • Patent number: 10519210
    Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13R?2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: December 31, 2019
    Assignee: Wake Forest University Health Sciences
    Inventors: Waldemar Debinski, Hetal Pandya, Denise Gibo
  • Patent number: 10512690
    Abstract: The present invention relates to nanoparticle compositions and, in particular, to composite polymeric nanoparticle compositions. A composite nanoparticle described herein comprises a photoluminescent polymeric component and a photo-thermal polymeric component. The photoluminescent polymeric component and the photo-thermal polymeric component can each comprise a single polymeric species or multiple polymeric species.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: December 24, 2019
    Assignee: Wake Forest University
    Inventors: Nicole Hope Levi, Christopher Michael MacNeill, Elizabeth Grace Gurysh, Louis Charles Argenta